ErbB2 represents a target for therapeutic intervention, and one that is sensitive to GW572016 therapy.
Introduction
The ERBB2 gene encodes an M r 185 kDa member of the ErbB family of transmembrane receptor tyrosine kinases, whose expression in certain normal tissues plays a role in regulating cell growth and differentiation (Sibilia and Wagner, 1995; Threadgill et al., 1995) . In addition, aberrant activation of ErbB2 in breast and other adenocarcinomas predicts for a poor clinical outcome (Slamon et al., 1987 (Slamon et al., , 1989 Gullick et al., 1991; Bacus et al., 1994) . Consequently, therapeutic monoclonal antibodies or small molecules, tyrosine kinase inhibitors targeting ErbB2 and/or the epidermal growth factor receptor (EGFR or ErbB1), have been developed. For example, trastuzumab a humanized antiErbB2 monoclonal antibody is approved for treating the 25-30% of breast cancers that overexpress ErbB2 or demonstrate ErbB2 gene amplification (Cobleigh et al., 1999) .
The regulation of ErbB receptor signaling is in large part mediated by a family of peptide ligands that bind to and activate ErbB receptors, for example, epidermal growth factor (EGF) and transforming growth factor a (TGFa) bind EGFR, while heregulin (HRG) binds ErbB3 and ErbB4 (Salomon et al., 1995; Reise and Stern, 1998) . Ligand binding induces ErbB receptor phosphorylation with subsequent formation of either receptor homo-or heterodimers. Phosphorylation of specific tyrosine residues contained within the cytoplasmic domain of ErbB receptors establishes docking sites for the phosphotyrosine-binding domain and/or Srchomology 2 (SH2) containing proteins. The activation of these adapter proteins initiates a signaling cascade involved in regulating cell growth and survival (Luttrell et al., 1994; Levkowitz et al., 1996; Tzahar et al., 1996; Olayioye et al., 1998; Hackel et al., 1999; Klapper et al., 2000) . ErbB2 is the preferred heterodimeric partner, potentiating ErbB receptor signaling (Stern and Kamps, 1988; Ullrich and Schlessinger, 1990; Wada et al., 1990; Karunagaran et al., 1996; Graus-Porta et al., 1997) . Although it lacks a peptide ligand, ErbB2 is transactivated through heterodimerization.
The biological effects elicited by ErbB receptor complexes vary depending upon the peptide ligands expressed in the tumor microenvironment as well as the cellular repertoire of ErbB receptors. Certain SH2 and phosphotyrosine-binding-domain proteins preferentially associate with specific ErbB receptors. For example, ErbB3 contains multiple cytoplasmic docking sites for the p85 subunit of phosphatidylinositol 3-kinase (PI3K), a prosurvival factor involved in resistance to hormonal/chemotherapy (Cheng et al., 1992; Prigent and Gullick, 1994; Soltoff et al., 1994; Bacus et al., 2002; Vivanco and Sawyers, 2002; Yakes et al., 2002) . Accordingly, ErbB3-containing heterodimers, specifically ErbB2-ErbB3 complexes, elicit potent mitogenic and prosurvival signals (Alimandi et al., 1995; Siegel et al., 1999) .
Full-length ErbB2 (p185
ErbB2
) undergoes proteolytic cleavage, shedding its extracellular domain (ECD), which is detectable in cell culture medium or patients' sera (Lin and Clinton, 1991; Zabrecky et al., 1991; Pupa et al., 1993) . Elevated levels of ErbB2 ECD in sera of breast cancer patients correlate with a poorer response to therapy (Kandl et al., 1994; Brandt-Rauf, 1995; Yamauchi et al., 1997; Colomer et al., 2000) . Truncated ErbB2 receptor (p95 ErbB2 ) exhibits increased autokinase activity and enhanced transforming efficiency compared with p185
ErbB2 , implicating the ECD as a negative regulator of ErbB2 kinase and oncogenic activity (Di Fiore et al., 1987; Bargmann and Weinberg, 1988; Segatto et al., 1988) . p95 ErbB2 expression correlates with positive lymph node metastasis in ErbB2-overexpressing breast cancers (Christianson et al., 1998; Molina et al., 2002) . It is therefore tempting to speculate that enhanced signaling through p95
ErbB2 -containing receptor complexes plays a role in metastatic progression. We now show that GW572016, a reversible inhibitor of ErbB2 and EGFR tyrosine kinases (Cockerill et al., 2001) , blocks p95 ErbB2 phosphorylation in breast cancer cell lines and tumor xenografts, whereas trastuzumab has no effect. In contrast to the full-length receptor, p95
ErbB2 almost exclusively associates with ErbB3 compared with EGFR, providing an explanation for the activation of p95
ErbB2 and ErbB3 by HRG. ErbB3-p95 ErbB2 heterodimer formation and subsequent activation of the PI3K-AKT prosurvival pathway provide a possible explanation for the link between p95
ErbB2 expression and metastatic progression in breast cancer. The inhibition of activated p95
ErbB2 by GW572016 has clinical implications for treating metastatic breast cancer and early-stage tumors that express p95
ErbB2 .
Results
Inhibition of p95 by GW572016 in ErbB2 overexpressing breast cell lines and its identification as the truncated ErbB2 receptor (p95
ErbB2 )
Exposure of ErbB2 overexpressing BT474 breast cancer cells to GW572016 (1 mM) for 16 h not only inhibited phosphorylation of p185 ErbB2 (Figure 1 , upper arrow) but also that of a 95 kDa phosphotyrosine protein (p95) (arrowhead). In addition, GW572016 inhibited p185 ErbB2 and p95 phosphorylation in S1 cells, a cell line established by single cell cloning of Hb4ac5.2 cells, a nonmalignant mammary epithelial line stably transfected with ErbB2 (Xia et al., 2002) . In contrast, p95 was not identified in the EGFR-overexpressing head and neck squamous cell carcinoma line HN5 or in parental Hb4a cells, although exposure to 5 mM GW572016 inhibited phosphorylation of p170 EGFR (lower arrow) and p185
ErbB2
, respectively (upper arrow). Proteolytic cleavage of the ECD of p185
ErbB2 results in a phosphorylated, truncated 95 kDa ErbB2 receptor (p95 ErbB2 ) (Christianson et al., 1998) . To determine if p95 and p95
ErbB2 are the same molecules, equal amounts of protein from the total cell extracts were analysed by Western blot using a ErbB2 mAb recognizing an epitope within the ErbB2 ECD (Figure 2, lanes 1-3) . Steadystate p185
ErbB2 protein levels (arrow) were unchanged in BT474 cells treated with vehicle alone (control) (lane 1), 0.5 mM GW572016 (lane 2), or 10 mg/ml trastuzumab (lane 3). In contrast, p95 was not identified using this particular mAb (Figure 2, lanes 1-3) .
However, p185 ErbB2 (arrow) and p95 (arrowhead) were identified in Western blots from BT474 whole-cell extracts using a ErbB2 Ab recognizing peptide 1243-1255, an intracytoplasmic ErbB2 sequence distinct from EGFR or ErbB3 (Figure 2 , lanes 4-6). Thus, p95 is the truncated ErbB2 receptor, p95
. Exposure to GW572016 (0.5 mM) for 24 h inhibited tyrosine phosphorylation of both p185
ErbB2 and p95 ErbB2 in BT474 cells (lane 8). Although p95
ErbB2 steady-state protein levels were somewhat reduced in trastuzumab (10 mg/ml) treated BT474 cells (lane 6), it had no effect on p95 Effects of GW572016 on the expression of phospho-ErbB2 and EGFR as well as a 95-kDa phosphotyrosine protein (p95) in BT474, HN5, S1, and Hb4a cell lines. Western blot analysis was performed on equal amounts of protein from whole-cell extracts using a pTyr mAb. Steady-state protein levels of phosphorylated p185
ErbB2 , p170 EGFR (arrows), and p95 (arrowhead) are shown. Cells were treated with vehicle alone (À) (DMSO at a final concentration of 0.1%) or GW572106 (1 or 5 mM as indicated for 24 h) ). Exponentially growing BT474 cells were cocultured with 0.5 mM GW572016 (lanes 2, 5, 8) or 10 mg/ml trastuzumab (lanes 3, 6, 9) for 24 h. Equal amounts of protein were separated by SDS-PAGE and then ErbB2, p95
ErbB2 , pTyr/p95 ErbB2 , and pTyr/ErbB2 steady-state protein levels assessed by Western blot. Blots were probed with the following Abs: (a) a ErbB2 ECD (lanes 1-3), (b) a intracytoplasmic ErbB2 peptide (aa 1243-1255) (lanes 4-6), and (c) a pTyr (lanes 7-9). Controls were treated with vehicle (0.1% DMSO) alone (lanes 1, 4, 7)
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GW572016 inhibits both p95
ErbB2 and p185 ErbB2 in breast cancer xenografts
We next examined the in vivo effects of GW572016 on p95
ErbB2 in mice bearing established BT474 tumor xenografts. As shown in Figure 3a , steady-state protein levels of total p185
ErbB2 and p95 ErbB2 were unchanged in tumor xenografts from vehicle (lanes 1-3), GW572016 (lanes 4-6), or trastuzumab (lanes 7-9) treated mice.
Using an antiphosphotyrosine antibody for Western blot analysis, we show that phospho-p185
ErbB2 steadystate protein levels were inhibited in BT474 tumors isolated from GW572016-treated mice (100 mg/kg/dose) ( Figure 3b , lanes 4-6). Similarly, GW572016 completely inhibited phospho-p95
ErbB2 steady-state protein levels (lanes 4-6). We also examined the effect of GW572016 on the phosphorylation state of tyrosine 1248 (Y1248), a key ErbB2 autophosphorylation site linked to downstream MAPK-Erk1/2 signaling. Using a phosphopeptide-specific antibody, we show that GW572016 inhibited Y1248 phosphorylation in p95
ErbB2 ( Figure 3c , lanes 4-6), whereas trastuzumab had little effect (lanes 7-9).
The inhibition of p185
ErbB2 and p95 ErbB2 phosphorylation by GW572016 in turn abrogated downstream signaling pathways involved in regulating tumor cell growth and survival. GW572016 inhibited p-Erk1/2 and p-AKT steady-state protein levels without affecting the total steady-state protein levels of either molecule ( Figure 4 , lanes 4-6). In addition, cyclin D steady-state protein levels were inhibited by GW572016. Conversely, trastuzumab (100 mg/kg) had little effect on p-Erk1/2, p-AKT, or cyclin D protein (lanes 7-9). Actin steadystate protein levels demonstrate equal loading of protein.
p95
ErbB2 preferentially associates with ErbB3
BT474 cells also express EGFR and ErbB3. To determine whether truncated p95 ErbB2 forms heterodimers, whole-cell extracts were subjected to immunoprecipitation (IP) with either a EGFR, ErbB2, or ErbB3 Abs followed by Western blot analysis using a pTyr mAb. As shown, EGF (50 ng/ml) increased EGFR phosphorylation in BT474 cells (Figure 5, upper panel ErbB2 and p185 ErbB2 were assessed using a phospho-tyrosine-specific mAb recognizing Y1248 Figure 4 GW572016 blocks the activation of MAPK-Erk1/2 and PI3K-AKT pathways and reduces cyclin D1/2 total steady-state protein levels in BT474 xenografts. Equal amounts of protein from tumor xenograft whole-cell extracts from vehicle (lanes 1-3), GW572016 (lanes 4-6), and trastuzumab-treated animals (lanes 7-9) were separated by SDS-PAGE and steady-state protein levels of total and phosphorylated forms of Erk1/2, and AKT assessed by Western blot. Cyclin D1/2 steady-state protein levels were also determined. Steady-state protein levels of actin confirm equal loading of protein
Heterodimerization of truncated p95
ErbB2 with ErbB3 W Xia et al p95 ErbB2 that coprecipitated with ErbB3 increased 4.5-fold ( Figure 5 , lower panel). Treatment with GW572016 blocked HRG-induced phosphorylation of coimmunoprecipitated p95
ErbB2 by 50%. In contrast, EGF had no effect on ErbB3 phosphorylation or the phosphorylation of coprecipitated p95
ErbB2 . HRG is also a ligand for ErbB4; however, we were unable to demonstrate ErbB4 expression in these cells (data not shown).
In vivo, treatment with GW572016 inhibited phosphorylation of p185
ErbB2 and p95 ErbB2 in BT474 tumor xenografts when compared with vehicle treatment alone (Figure 6a , upper and lower panels). We next examined BT474 tumor xenografts for the presence of ErbB3-p95
ErbB2 heterodimers in mice treated with GW572016 (100 mg/kg/dose) or vehicle alone. ErbB3 IPs were analysed by Western blot using either a pTyr (Figure 6b The cytoplasmic domain of ErbB3 contains at least seven tyrosine residues that serve as docking sites for the p85 subunit of PI3K Soltoff et al., 1994) . Phosphorylation of these tyrosine residues leads to AKT phosphorylation and activation. Since ErbB2 preferentially associates with ErbB3 in BT474 breast cancer cells, we next examined the effects of HRG, an ErbB3 ligand, on the MAPK-Erk1/2 and PI3K-AKT pathways. Exposing BT474 cells to EGF (50 ng/ml) for 15 min increased p-Erk1/2 steady-state protein levels, an effect blocked by GW572016 (1 mM) (Figure 7) . AKT phosphorylation increased approximately 40% in response to HRG (5 mM). Although ErbB2 -ErbB3 heterodimers in BT474 cells and the effect of GW572016 on EGF-or HRG-induced phosphorylation of p95
ErbB2 , p185 ErbB2 , and ErbB3. Cells were cultured in serum-free medium containing 1.5% BSA with or without 1 mM GW572016 for 16 h and then exposed to EGFR (50 ng/ml) or HRG (5 mM) for 15 min prior to harvesting. Phospho-p95
ErbB2 , p185 ErbB2 , and ErbB3 were assessed by IP (as indicated in the upper, middle, and lower panels) Western blot using a pTyr mAb. Quantification was performed using an Odyssey Infrared Imaging System. These results are representative of three independent experiments 
Discussion
Despite recent advances in breast cancer therapy, nearly 40 000 people died from metastatic breast cancer in 2001. Elucidating the pathways regulating breast cancer cell growth and survival might provide additional targets for therapeutic intervention. Proteolytic cleavage of the ErbB2 ECD results in the expression of a truncated ErbB2 receptor (p95 ErbB2 ), which exerts potent oncogenic signals in preclinical models (Di Fiore et al., 1987; Bargmann and Weinberg, 1988; Segatto et al., 1988) . Moreover, tumor expression of p95
ErbB2 has been linked to metastatic progression in ErbB2-overexpressing breast cancers (Christianson et al., 1998; Molina et al., 2002) . Whereas the role of p185 ErbB2 in regulating breast cancer cell growth and survival has been extensively studied, relatively little is known about p95
ErbB2 . Here, we show that p95 ErbB2 is constitutively activated in breast cancer cell lines and tumor xenografts. Since ErbB2 tyrosine phosphorylation is a biochemical marker of increased cell transformation activity, these data implicate activated, phospho-p95 ErbB2 as playing a role in metastatic progression of breast cancer. We now show that p95 ErbB2 preferentially heterodimerizes with ErbB3 in BT474 breast cancer cells and tumor xenografts. Consequently, HRG, but not EGF, stimulates p95
ErbB2 phosphorylation, which has consequences on downstream mediators of tumor growth and survival (e.g., AKT). These data identify p95
ErbB2 as a target for therapeutic intervention.
Engineered truncated ErbB2 receptors possess enhanced cell transformation activity compared with p185
ErbB2 (Di Fiore et al., 1987; Bargmann and Weinberg, 1988; Segatto et al., 1988) . Deletions within the ECD of ErbB2 increase ErbB2 autokinase and transformation activities, implicating sites within the ECD as exerting repressive effects on ErbB2 activity. These findings are reminiscent of a deletion mutation within the ECD of EGFR (vIII mutation) present in a variety of malignancies and associated with constitutive, ligandindependent activation of EGFR (Wong et al., 1992) . The increased oncogenic properties of p95
ErbB2 are consistent with the link between p95
ErbB2 expression and metastatic progression in ErbB2-overexpressing breast cancers.
To elucidate the link between p95 ErbB2 expression in breast cancer and metastatic progression, we investigated the regulation of p95
ErbB2 in human breast cancer cells and tumor xenografts. Since ErbB receptors signal primarily through heterodimer complexes, it was necessary to address whether p95
ErbB2 forms heterodimers, and if so, with what ErbB receptors. ErbB3 and p185
ErbB2 are frequently coexpressed in breast cancers (Lemoine et al., 1992; Rajkumar and Gullick, 1994; Alimandi et al., 1995; Siegel et al., 1999) . Moreover, ErbB3-p185
ErbB2 heterodimers represent one of the most potent mitogenic, transforming receptor complexes.
Coexpression of ErbB3 and p185
ErbB2 , but not EGFR and ErbB3, synergizes to transform NIH3T3 cells, whereby ErbB2 transphosphorylates and activates ErbB3 (Alimandi et al., 1995) . Since ErbB3 contains multiple docking sites for the SH2 domain of the p85 subunit of PI3K, ErbB3-containing heterodimers are potent activators of the PI3K-AKT growth and survival pathway Soltoff et al., 1994) . Consequently, cotransfection of ErbB3 and p185 ErbB2 activates the PI3K-AKT pathway. In addition, heterodimerization with p185
ErbB2 enhances the binding affinity of HRG for ErbB3. In this context, aberrant activation of the PI3K-AKT pathway in breast and other carcinomas predicts for a poorer clinical outcome (Cheng et al., 1992; Vivanco and Sawyers, 2002; Yakes et al., 2002) .
Here, we show that p95 ErbB2 preferentially associates with ErbB3, whereas p185
ErbB2 heterodimerizes with both EGFR and ErbB3. This provides an explanation for the regulation of p95
ErbB2 phosphorylation by HRG, but not EGF with subsequent downstream activation of AKT. However, HRG-induced ErbB3 phosphorylation was not effectively blocked by GW572016 despite inhibition of p185
ErbB2 and p95 ErbB2 tyrosine phosphorylation ( Figure 5, lower panel) . Although HRG also activates ErbB4, we were unable to detect ErbB4 in these cells (data not shown). These data are consistent with a recent observation, suggesting that some of the biological effects of HRG may be mediated via a mechanism independent of ErbB3 or ErbB4 (Beerli et al., 1995) .
GW572016 blocks phosphorylation of EGFR, p185
ErbB2 , Erk1/2, and AKT, as well as inhibiting cyclin D protein levels in human tumor cell lines and Figure 7 GW572016 inhibits activation of Erk1/2 and AKT by EGF and HRG in BT474 cells. Exponentially growing cells were treated as indicated in Material and methods. GW572016 was added for 24 h. Equal amounts of protein were analysed by Western blot for steadystate protein levels of total and phosphorylated forms of Erk1/2 and AKT. Proteins were visualized using fluorescent-labeled secondary Abs and quantified by Odyssey Infrared Imaging System. These results are representative of three independent experiments Heterodimerization of truncated p95
ErbB2 with ErbB3 W Xia et al xenografts (Rusnak et al., 2001; Xia et al., 2002) . Although preliminary, GW572016 has shown antitumor activity in early-phase clinical trials in heavily pretreated subjects with metastatic cancers, notably breast cancer (manuscript in preparation). In this context, we now show that GW572016 inhibits p95 ErbB2 phosphorylation, blocking the activation of downstream Erk1/2, AKT, and cyclin D protein levels in BT474 breast cancer cells and tumor xenografts. In contrast, trastuzumab, which binds to the ECD of ErbB2, did not block p95 ErbB2 activation. In our hands, trastuzumab had little effect on steady-state protein levels of p-Erk1/2, p-AKT, and cyclin D in tumor cell lines and tumor xenografts. The mechanism(s) by which trastuzumab exerts its antitumor activity remains unknown and is likely multifactorial, mediated through both immunological effects, which are independent of its modulation of ErbB2 phosphorylation, as well as effects on signal transduction pathways. Nonetheless, it is tempting to speculate that signaling through p95
ErbB2
-containing heterodimers, which would not be affected by an antibody like trastuzumab directed against the ErbB2 ECD, might contribute to trastuzumab resistance, which is most likely a multifactorial process. p95 ErbB2 has been implicated in the progression of ErbB2-overexpressing breast cancers. Cleavage of the ECD of ErbB2 appears to be mediated by an MMP family member (Codony-Servat et al., 1999) . Increased MMP activity stimulates tumor angiogenesis and degradation of the extracellular matrix, both key events for metastases (Stamenkovic, 2000) . During metastatic progression, increased MMP activity may explain the increased cleavage of p185
ErbB2 . In addition, ErbB3-p95
ErbB2 heterodimers potently activate the PI3K-AKT pathway, the latter being implicated in hormonal/ chemotherapy resistance. This explanation is particularly relevant to breast cancer where coexpression of ErbB3 and ErbB2 occurs frequently. However, the nature of the signal generated by ErbB receptor complexes is not only dependent upon the repertoire of ErbB receptors expressed by tumors but also the ErbB receptor ligands expressed in the tumor microenvironment. HRG, an ErbB3/ErbB4 ligand, is expressed in the microenvironment of many tumors, notably breast cancer (Tsai et al., 2003) . Our data suggest that HRG, but not EGF, activates p95 ErbB2 -ErbB3 heterodimers, which has downstream effects on AKT activation and clinical implications related to disease progression and resistance to therapy.
In the future, cancer therapy will be based on molecular tumor profiles rather than histology. Elucidating the biological effects of targeted therapies will help identify those factors regulating tumor cell growth and survival, thereby facilitating identification of likely responders and providing a rationale for therapeutic strategies to overcome resistance. Although trastuzumab may reduce ErbB2 cleavage by binding to the ECD (Molina et al., 2001) (Cockerill et al., 2001) . GW572016 for cell culture work was dissolved in DMSO.
Cell cultures
BT474 cells were cultured in RPMI 1640 supplemented with Lglutamine, 10% FBS (Hyclone), and 5 m/ml insulin. HB4a cells were cultured under identical conditions to BT474 cells, in addition, with 10 mg/ml hydrocortisone. S1 cells were cultured in RPMI 1640 supplemented with L-glutamine, 10% FBS, and 50 mg/ml hygromycin. HN5 cells were cultured in DMEM supplemented with high glucose and 10% fetal bovine serum (FBS) . All cell cultures were maintained in a humidified atmosphere of 5% CO 2 at 371C.
EGF and HRG stimulation experiments
Cells were seeded at low density in serum-free medium supplemented with 1.5%. BSA, and then exposed for 6-24 h to GW572016 at various concentrations indicated in the figure legends, or 10 mg/ml trastuzumab. Cells were stimulated with 50 ng/ml EGF or 5 nM HRG for 15 min, harvested on ice, and then lysed in RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 0.25% (w/v) deoxycholate, 1% NP-40, 5 mM sodium orthovanadate, 2 mM sodium fluoride, and a protease inhibitor cocktail).
IP and Western blots
IPs and Western blots were performed as previously described (Xia et al., 2002) . Briefly, protein concentrations were determined using a modification of the Bradford method (Bio-Rad Laboratory), and equal amounts of protein subjected to IP and Western blot. Efficiency and equal loading of proteins were evaluated by Ponceau S staining. Membranes were blocked for 1 h in TBS (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2.7 mM KCl) containing 4% (w/v) low-fat milk or 3% BSA (w/v). Membranes were then probed with specific antibodies recognizing target proteins, which were visualized with the SuperSignal West Femto Maximum sensitivity substrate kit (Pierce). Other blots were visualized and quantification performed using the Odyssey Infrared Imaging System (LI-COR, Inc., Lincoln, NE, USA). For the Odyssey, membranes were incubated with fluorescent-labeled secondary antibody at 1 : 10 000 dilution with 3% BSA in PBS for 60-min protected from light. After washing in PBS þ 0.1% Tween-20, the membranes were scanned using an Odyssey Infrared Imaging System.
Tumor xenografts
BT474 tumors were maintained by serial passage of fragments into female C.B-17 SCID mice, for up to 10 passages. Once tumor implants were palpable, mice were administered either vehicle (0.5% hydroxypropylmethylcellulose/0.1% Tween 80) given orally (p.o.), five doses of GW572016 at 100 mg/kg (p.o.) twice daily at 8 h intervals, or trastuzumab at 100 mg/kg given intraperitoneally (i.p.) daily for 3 days. Tumors were removed 4 h after the last dose, frozen in liquid nitrogen, and stored at À801C until analysis. For the terminal biopsy, mice were euthanized with CO 2 inhalation. Cell extracts were prepared by homogenization in RIPA buffer at 41C.
